ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
87.83
+2.32 (+2.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close85.51
Open85.89
Bid85.01 x 800
Ask87.83 x 1100
Day's Range85.89 - 88.56
52 Week Range65.63 - 133.74
Volume703,344
Avg. Volume911,663
Market Cap2.869B
Beta (3Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)-10.75
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est158.47
  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool2 days ago

    3 Top Biotech Stocks to Buy Right Now

    These three biotech stocks should turn out to be outstanding long-term growth vehicles.

  • Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences
    Motley Fool6 days ago

    Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences

    These two biotechs could have a tortoise-and-hare kind of race going on.

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of ICPT earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 Intercept Pharmaceuticals Inc Earnings Call

  • GlobeNewswire14 days ago

    Intercept to Present at Upcoming Investor Conferences in May

    NEW YORK, May 10, 2019 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
    Zacks15 days ago

    Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

    Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.

  • 2 Reasons Intercept Pharmaceuticals Stock Tanked in April
    Motley Fool16 days ago

    2 Reasons Intercept Pharmaceuticals Stock Tanked in April

    Intercept's shares continued to slide last month. Here's why.

  • Benzinga16 days ago

    The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 8) Alcon AG (NYSE: ALC ) BioSig Technologies Inc (NASDAQ: ...

  • GlobeNewswire16 days ago

    Intercept Pharmaceuticals Announces Proposed Offerings of $200 Million of Common Stock and $200 Million of Convertible Senior Notes due 2026

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it is commencing an underwritten public offering to sell, subject to market and other conditions, up to $200 million of its common stock. Intercept also announced that it is commencing an underwritten public offering to sell, subject to market and other conditions, up to $200 million aggregate principal amount of convertible senior notes due 2026 (the “Notes”).  The Notes will be senior unsecured obligations of Intercept and will mature on May 15, 2026, unless earlier converted, redeemed or repurchased.

  • What You Need to Know About Intercept Pharmaceuticals' Great Q1 Performance
    Motley Fool16 days ago

    What You Need to Know About Intercept Pharmaceuticals' Great Q1 Performance

    The biotech turned in another strong quarterly performance with rising sales for Ocaliva and a regulatory filing for a new indication on the way.

  • Intercept Pharmaceuticals Inc (ICPT) Q1 2019 Earnings Call Transcript
    Motley Fool17 days ago

    Intercept Pharmaceuticals Inc (ICPT) Q1 2019 Earnings Call Transcript

    ICPT earnings call for the period ending March 31, 2019.

  • Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue Estimates
    Zacks17 days ago

    Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue Estimates

    Intercept (ICPT) delivered earnings and revenue surprises of -17.90% and 1.04%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Will Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Earnings Grow In The Next Couple Of Years?
    Simply Wall St.17 days ago

    Will Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Earnings Grow In The Next Couple Of Years?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) announced its latest earnings update in December 2018...

  • Associated Press17 days ago

    Intercept: 1Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of $3.03. The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire17 days ago

    Intercept Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2019. “Our Phase 3 REGENERATE readout demonstrating OCA’s anti-fibrotic benefit in patients with NASH has been a watershed moment for the liver community and underscores our unique competitive opportunity to become the first approved NASH therapy,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept.

  • Markit18 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high and has been increasing * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is high for ICPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ICPT. Sentiment has worsened and traders added to their bearish short positions on April 12. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.74 billion over the last one-month into ETFs that hold ICPT are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire24 days ago

    Intercept to Announce First Quarter 2019 Financial Results on May 8, 2019

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2019 financial results prior to market open on Wednesday, May 8, 2019. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

  • 2 Reasons Gilead Sciences' NASH Program Could Bounce Back
    Motley Fool28 days ago

    2 Reasons Gilead Sciences' NASH Program Could Bounce Back

    It's been a rough few years, but an unexpected partnership could put the biotech's liver disease program back on top.

  • Here’s What Hedge Funds Think About Intercept Pharmaceuticals Inc (ICPT)
    Insider Monkey29 days ago

    Here’s What Hedge Funds Think About Intercept Pharmaceuticals Inc (ICPT)

    While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]

  • Benzingalast month

    Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment

    A little more than two months after it reported failed results for a late-stage study dubbed STELLAR-4, Gilead said Thursday that another Phase 3 study dubbed STELLAR-3 that evaluated its selonsertib for patients with bridging fibrosis due to NASH did not meet the pre-specified week 48 primary endpoint. The endpoint was for a histologic improvement in fibrosis of more than one stage without worsening of NASH. NASH has no approved drug treatment and therefore offers huge potential for the first mover.

  • 5 Top Pharmaceutical Stocks to Buy in 2019
    Motley Foollast month

    5 Top Pharmaceutical Stocks to Buy in 2019

    Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Foollast month

    3 Top Healthcare Stocks to Buy in April

    GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.

  • Gilead to Collaborate with Novo Nordisk for NASH Treatment
    Zackslast month

    Gilead to Collaborate with Novo Nordisk for NASH Treatment

    Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.

  • Why Intercept's Success Was a Big Disappointment
    Motley Foollast month

    Why Intercept's Success Was a Big Disappointment

    The complete presentation of results from the Regenerate trial wasn't exactly what investors were expecting.